Ocular Allergy: Calming the Itchy, Watery Eye

The itch is the diagnosis

Three red eyes sit side by side in every clinic — and one symptom separates them. The red eye is one of the most common presentations in medicine, and the trap is treating all red eyes alike. Three patterns recur. The allergic eye itches — that is its signature — and comes with watering, a jelly-like swelling of the conjunctiva (chemosis), and usually both eyes at once. The dry eye is gritty and burning rather than itchy, worse through the day and on screens, and is covered in the Dry-eye chapter. The infected eye is painful or sticky: a bacterial conjunctivitis glues the lashes with pus, while pain with photophobia and reduced vision points to something serious like keratitis or uveitis that needs urgent referral, not an antihistamine. When itch leads the story and the vision is preserved and the cornea is clear, you are on allergic ground.

The mast cell: one cell, one cascade

The conjunctiva is richly stocked with mast cells, and they are the engine of the whole disease. On first exposure, an allergen (pollen, dust mite, animal dander) drives the immune system to make IgE antibodies that coat the surface of these mast cells. On the next exposure the allergen bridges two IgE molecules, and the mast cell degranulates — it bursts open its stores in seconds. Out pours pre-formed histamine, along with newly made mediators (prostaglandins, leukotrienes) and, hours later, an influx of eosinophils. Histamine is what you feel first: it triggers the itch by stimulating nerve endings, dilates the conjunctival vessels to give redness, and leaks fluid out of them to produce the glassy chemosis and watering. So the clinical picture — itch, redness, swelling, tearing — is simply histamine's fingerprints. This is the same mast-cell axis that produces a hive in the skin, which is why the Dermatology / Inflammation chapter on urticaria reads like a mirror image of this one: same cell, same mediator, same drug classes, different surface.

Mapping the drugs onto the mast-cell axis

Every drop belongs somewhere on the same short cascade: block the histamine, or block the cell. Topical antihistamines (H1-receptor blockers such as azelastine, epinastine and levocabastine) work downstream, on the histamine that is already out. They plug the H1 receptor so histamine cannot dock on it, killing the itch within minutes — fast, on-demand relief, but they do nothing to stop the mast cell firing again. Mast-cell stabilisers (sodium cromoglicate, lodoxamide, nedocromil) work upstream, keeping the granules shut so the cell releases less on the next allergen hit. They are preventive, not rescue: they take days of regular use to build effect, so the classic teaching is to start them before the pollen season, not on the day symptoms peak. The modern first-line drops are the dual-action agents — olopatadine and ketotifen — which block the H1 receptor and stabilise the mast cell in a single molecule: immediate relief plus ongoing prevention, which is why they have largely displaced the single-mechanism drops. Then two adjuncts sit off the main axis. Topical vasoconstrictors / decongestants (naphazoline and related alpha-agonists) whiten the eye by clamping the dilated conjunctival vessels — cosmetic, short-term relief only, because prolonged use produces rebound redness (conjunctivitis medicamentosa); this is the ocular face of the alpha-agonist pharmacology in the Autonomic chapter. And oral antihistamines help the sneezing, itchy-nose patient with systemic atopy, but their anticholinergic drying reduces the tear film and can leave the eye itself more irritable — a real trade-off in someone whose eyes are already the problem.

When allergy turns serious: vernal, atopic and giant papillary disease

Seasonal and perennial allergic conjunctivitis are common and harmless to sight. But a smaller group of chronic allergic diseases can threaten the cornea, and they change the management. Vernal keratoconjunctivitis (VKC) strikes children and young men, often in warm dry climates, with intense itch, thick ropey mucus, and giant "cobblestone" papillae under the upper lid. Its danger is the shield ulcer — a sterile, sight-threatening defect that can form on the upper cornea from a mix of inflammation and mechanical rubbing by those papillae. Atopic keratoconjunctivitis (AKC) is its adult cousin, seen in patients with eczema and asthma, and carries risks of corneal scarring and even keratoconus. Giant papillary conjunctivitis (GPC) is mechanical-allergic: giant papillae driven by a chronically rubbing contact lens or a suture or prosthesis, and the first-line treatment is often simply to remove the offending stimulus and rest the lens. The unifying lesson is that once the cornea is at risk, topical antihistamines alone are not enough — you have to suppress the inflammation itself.

Escalating means borrowing the anti-inflammatory heavy artillery — with all its ocular caveats. For a sight-threatening flare of VKC or AKC, a short, pulsed course of a topical corticosteroid quickly quells the inflammation. But steroids on the eye carry three well-known prices — raised intraocular pressure and steroid-induced glaucoma, cataract formation with prolonged use, and a blunted defence that lets infection (especially herpes simplex) take hold and worsen. Those caveats are taught in full in the Ocular steroids chapter, and they are the reason steroids are used as a brief bridge, not a long-term crutch. To hold the disease down without that toll, the steroid-sparing agents are topical ciclosporin and tacrolimus — calcineurin inhibitors that damp the T-cell arm of the inflammation and let you taper the steroid off. Ciclosporin is the same drug that anchors moderate-to-severe Dry-eye treatment, and it reappears here for the same reason: chronic surface inflammation needs a maintenance immunomodulator, not endless steroid. Alongside all of this, never forget the non-drug measures, which genuinely reduce the mediator load: identify and avoid the allergen where possible, apply cool compresses to soothe the itch and shrink the swelling, and use preservative-free lubricants — artificial tears — to physically dilute and wash allergen off the ocular surface.